ACET
Adicet Bio, Inc.
Set alert
3.42 USD -0.16 -4.47%
3.33 Day range 3.74
3.42 52-week range 12.46
- YTD
- -59.38%
- 1 year
- -72.55%
- Open
- 3.74
- Prev close
- 3.58
- Mkt cap
- 32.02M
- Vol
- 242.49K
- Avg vol
- 196.92K
- EPS
- -10.42
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.33
- High
- 3.74
- Forward P/E
- -0.69
- Beta
- 1.70
- Short ratio
- 7.04
- Inst. own
- 76.44%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.16
- 200-d avg
- 1.48
- 1y target
- 6.40
Key statistics
- Market cap
- 75.50M
- Enterprise value
- -97.82M
- Trailing P/E
- 0.00
- Forward P/E
- -0.69
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.23
- EPS (TTM)
- -1.70
- Beta
- 1.70
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -55.26M
- Total cash
- 224.07M
- Total debt
- 19.13M
- Return on equity
- -57.91%
- Shares outstanding
- 82.40M
- Short % of float
- 4.93%
- 50-day average
- 1.16
- 200-day average
- 1.48
Analyst view
Consensus: buy
Buy
Price target (mean) 6.40 +87.1% upside
Now 3.42
- Target (low)
- 4.00
- Target (mean)
- 6.40
- Target (high)
- 8.00
Ratings (0m) 7 5 buy · 2 hold · 0 sell
- Strong buy0
- Buy5
- Hold2
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.355.
Financials — quick view
ACET Revenue — quarterly 0
ACET Net income — quarterly -21.36M
ACET EPS — quarterly -1.99
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 19, 2024 | HC Wainwright & Co. | reit | Neutral | Neutral |
| Nov 18, 2024 | HC Wainwright & Co. | reit | — | Neutral |
| Aug 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 14, 2024 | Canaccord Genuity | main | Buy | Buy |
| Jul 8, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 24, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Adicet Bio, Inc.
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- adicetbio.com
News
- Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
- Adicet Bio's Prula-Cel Delivers 54% Lupus Remission Rate at 12 Months
- Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
- Wedbush Maintains Outperform on Adicet Bio, Raises Price Target to $28
- Adicet Bio, Inc. (ACET) Discusses Positive Prula-cel Data and Plans for Pivotal Study in Lupus Nephritis Transcript
- 12 Health Care Stocks Moving In Monday's Intraday Session
- HC Wainwright & Co. Maintains Buy on Adicet Bio, Raises Price Target to $34
- Adicet Bio Announces Safety And Efficacy Data From Phase 1 Study Evaluating Prulacabtagene Leucel In Patients With Systemic Lupus Erythematosus With Or Without Lupus Nephritis; Prula-Cel Generally Well Tolerated With No CRS Greater Than Grade 2 And No IEC-HS Or ICANS
- Adicet Bio Announces Positive Safety and Efficacy Data from Prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis
- Why Webuy Global Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Your note
Sign in to keep a note on ACET — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHODAKEWITZ JEFFREY | Director | Stock Award(Grant) | Jun 4, 2024 | 11,800 |
| DUBIN STEVE | Director | Stock Award(Grant) | Jun 4, 2024 | 16,800 |
| GORDON CARL L | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Jun 4, 2024 | 11,458,900 |
| HARVEY BRIAN NICHOLAS | Chief Financial Officer | Stock Award(Grant) | Jan 23, 2024 | 99,800 |
| JAKOBOVITS AYA | Director | Stock Award(Grant) | Jun 4, 2024 | 862,562 |
| KAUFFMAN MICHAEL G | Director | Sale | Jun 4, 2024 | 5,900 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Orbimed Advisors LLC. | 13.89% | 11,447,140 | 10.49M | Sep 29, 2024 |
| Tang Capital Management, LLC | 9.97% | 8,216,960 | 7.53M | Sep 29, 2024 |
| RA Capital Management, L.P. | 9.15% | 7,541,000 | 6.91M | Sep 29, 2024 |
| Goldman Sachs Group Inc | 4.56% | 3,759,997 | 3.44M | Sep 29, 2024 |
| Vanguard Group Inc | 3.89% | 3,205,882 | 2.94M | Sep 29, 2024 |
| Carlyle Group Inc. | 3.58% | 2,948,718 | 2.70M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.51% | 2,072,101 | 1.90M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.31% | 1,079,499 | 989.04K | Sep 29, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Fund | 0.80% | 660,300 | 604.97K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.43% | 351,417 | 321.97K | Oct 30, 2024 |
| Fidelity Enhanced Small Cap ETF | 0.27% | 222,485 | 203.84K | Oct 30, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.23% | 191,300 | 175.27K | Sep 29, 2024 |